Taking T-Cell Oncotheraphy Off-the-Shelf

被引：15

作者：

Mo, Feiyan ^{[1
,2
,3
]}

Mamonkin, Maksim ^{[1
,2
,3
,4
,5
]}

Brenner, Malcolm K. ^{[1
,2
,3
,5
]}

Heslop, Helen E. ^{[1
,2
,3
,5
]}

机构：

[1] Texas Childrens Hosp, Ctr Cell & Gene Therapy, Baylor Coll Med, Houston, TX 77030 USA

[2] Houston Methodist Hosp, Houston, TX 77030 USA

[3] Baylor Coll Med, Grad Program Translat Biol & Mol Med, Houston, TX 77030 USA

[4] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA

[5] Baylor Coll Med, Dan L Duncan Comprehens Canc Ctr, Houston, TX 77030 USA

来源：

TRENDS IN IMMUNOLOGY | 2021年 / 42卷 / 03期

关键词：

CHIMERIC-ANTIGEN-RECEPTOR; MINOR HISTOCOMPATIBILITY ANTIGENS; NATURAL-KILLER-CELLS; VERSUS-HOST-DISEASE; NK CELLS; IMMUNOTHERAPY; CAR; EXPRESSION; PLATFORM; TUMOR;

D O I：

10.1016/j.it.2021.01.004

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Banked allogeneic or 'off-the-shelf' (OTS) T cells from healthy human donors are being developed to address the limitations of autologous cell therapies. Potential challenges of OTS T cell therapies are associated with their allogeneic origin and the possibility of graft-versus-host disease (GvHD) and host-versus-graft immune reactions. While the risk of GvHD from OTS T cells has been proved to be manageable in clinical studies, approaches to prevent immune rejection of OTS cells are at an earlier stage of development. We provide an overview of strategies to generate OTS cell therapies and mitigate alloreactivity-associated adverse events, with a focus on recent advances for preventing immune rejection.

引用

页码：261 / 272

页数：12

共 76 条

[11] Co-stimulatory members of the TNFR family: Keys to effective T-cell immunity?
Croft, M
[J]. NATURE REVIEWS IMMUNOLOGY, 2003, 3 (08) : 609 - 620
[12] The TNF family in T cell differentiation and function - Unanswered questions and future directions
Croft, Michael
[J]. SEMINARS IN IMMUNOLOGY, 2014, 26 (03) : 183 - 190
[13] 'Off-the-shelf' allogeneic CAR T cells: development and challenges
Depil, S.
Duchateau, P.
Grupp, S. A.
Mufti, G.
Poirot, L.
[J]. NATURE REVIEWS DRUG DISCOVERY, 2020, 19 (03) : 185 - 199
[14] Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients
Deuse, Tobias
Hu, Xiaomeng
Gravina, Alessia
Wang, Dong
Tediashvili, Grigol
De, Chandrav
Thayer, William O.
Wahl, Angela
Garcia, J. Victor
Reichenspurner, Hermann
Davis, Mark M.
Lanier, Lewis L.
Schrepfer, Sonja
[J]. NATURE BIOTECHNOLOGY, 2019, 37 (03) : 252 - +
[15] Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection
Eyquem, Justin
Mansilla-Soto, Jorge
Giavridis, Theodoros
van der Stegen, Sjoukje J. C.
Hamieh, Mohamad
Cunanan, Kristen M.
Odak, Ashlesha
Goenen, Mithat
Sadelain, Michel
[J]. NATURE, 2017, 543 (7643) : 113 - +
[16] Minor histocompatibility antigens in human stem cell transplantation
Falkenburg, JHF
van de Corput, L
Marijt, EWA
Willemze, R
[J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (09) : 743 - 751
[17] Specificity of T-cell alloreactivity
Felix, Nathan J.
Allen, Paul M.
[J]. NATURE REVIEWS IMMUNOLOGY, 2007, 7 (12) : 942 - 953
[18] A Paradigm Shift on the Question of B Cells in Transplantation? Recent Insights on Regulating the Alloresponse
Firl, Daniel J.
Benichou, Gilles
Kim, James I.
Yeh, Heidi
[J]. FRONTIERS IN IMMUNOLOGY, 2017, 8
[19] GALE RP, 1986, LANCET, V1, P1468
[20] FT596: Translation of First-of-Kind Multi-Antigen Targeted Off-the-Shelf CAR-NK Cell with Engineered Persistence for the Treatment of B Cell Malignancies
Goodridge, Jode P.
Mahmood, Sajid
Zhu, Huang
Gaidarova, Svetlana
Blum, Robert
Bjordahl, Ryan
Cichocki, Frank
Chu, Hui-yi
Bonello, Greg
Lee, Tom
Groff, Brian
Meza, Miguel
Walcheck, Bruce
Malmberg, Karl-Johan
Miller, Jeffrey S.
Kaufman, Dan S.
Valamehr, Bahram
[J]. BLOOD, 2019, 134

← 1 2 3 4 5 6 7 8 →